TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33211886
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (3 g/day)
Study: 33211886
Drug: Citrate mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate mixture (7 g/day)
Study: 36249246
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS intervention for improving feeding practices
Study: 33919722
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL extra-virgin olive oil supplement
Study: 36088325
Drug: Tea and
Normalized name: Clenia Plus Green Tea and Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea and coffee (Staining agents)
Study: 36088325
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (Staining agent)
Study: 35933278
Drug: 1-week PrEP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week PrEP with human diploid cell culture rabies vaccine (HDCV) IM (Group 1)
Study: 35933278
Drug: 3-week PrEP
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week PrEP with human diploid cell culture rabies vaccine (HDCV) IM (Group 2)
Study: 35933278
Drug: 1-week PrEP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week PrEP with Vero cell rabies vaccine (PVRV) IM (Group 4)
Study: 35933278
Drug: 1-week PrEP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week PrEP with Vero cell rabies vaccine (PVRV) ID (Group 5)
Study: 35669363
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic drugs or diet control, appropriate exercise
Study: 35963558
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (d-methylphenidate + guanfacine)
Study: 35368384
Drug: Ruxolitinib 5
Normalized name: ruxolitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg twice per day
Study: 33019874
Drug: Antibody-based therapies
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-based therapies (PEMs from BCC)
Study: 33019874
Drug: Small molecule-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule-based therapies (PEMs from BCC)
Study: 36181554
Drug: Digital therapeutic
Normalized name: digital therapeutics, amblyopia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital therapeutic app delivering cognitive behavioral therapy (BT‐001)
Study: 32672489
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib (IM) and hydroxyurea (HU) combination therapy
Study: 32672489
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib (IM) monotherapy
Study: 36435838
Drug: Tailored lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored lifestyle and intensively supplemented with oral nutrition support (Group SS)
Study: 33826038
Drug: Adapted Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Cognitive Behavioral Therapy (CBT)
Study: 36121664
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with a history of digital rectal examination or PSA testing
Study: 32730026
Drug: Self-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intervention
Study: 32730026
Drug: Self-administered plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered plus telephone intervention
Study: 34412668
Drug: α1-adrenergic blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: α1-adrenergic blocker (doxazosin 0.05 mg/kg)
Study: 33769117
Drug: Fingolimod (0.5–1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (0.5–1.25 mg/day)
Study: 35276329
Drug: 130 mg
Normalized name: pectin 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 mg ustekinumab
Study: 35276329
Drug: approximately 6
Normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
Approvals — FDA: no, EMA: no, PMDA: no
Description: approximately 6 mg/kg ustekinumab
Study: 34799501
Drug: Dexamethasone 12
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg
Study: 34117162
Drug: modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified directly administered ART (mDAART) plus standard of care
Study: 33958719
Drug: Bovine milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk-based infant formula with 7.2 g MOS/L
Study: 34113435
Drug: Modular intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modular intervention to improve paternal involvement in infant and young child feeding (IYCF); implemented through monthly visits for six months.
Study: 32423247
Drug: Intranasal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroids (Nasacort)
Study: 32423247
Drug: Placebo (Ayr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Ayr saline spray)
Study: 35505251
Drug: HDACi anti-epileptic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDACi anti-epileptic drugs (AEDs)
Study: 35505251
Drug: Other anti-epileptic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anti-epileptic drugs (AEDs)
Study: 38436495
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (4 mg)
Study: 33008451
Drug: Dexmedetomidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.8 μg/kg administered for 10 min before anesthesia)
Study: 33720960
Drug: Regimen D
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D (injection gentamicin once daily for 2 days plus oral amoxicillin twice daily for 7 days)
Study: 33720960
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (injection gentamicin once daily plus oral amoxicillin twice daily, both for 7 days)
Study: 33720960
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (once daily injection gentamicin plus injection procaine penicillin for 2 days, thereafter oral amoxicillin twice daily for 5 days)
Study: 33720960
Drug: Regimen E
Normalized name: ASPIRIN 325 mg ORAL TABLET, COATED [Bayer Aspirin Regimen enteric coated]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen E (oral amoxicillin twice daily for 7 days)
Study: 33720960
Drug: Reference regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference regimen A (injection gentamicin plus injection procaine penicillin both once daily for 7 days)
Study: 32502358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medication only)
Study: 37310790
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks
Study: 34814693
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections at the time of surgery
Study: 33305552
Drug: Beta-alanine (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (4.8 g·day-1 for four weeks)
Study: 32268436
Drug: Early-onset abiraterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-onset abiraterone acetate plus prednisone (AA+P) therapy
Study: 32268436
Drug: Late-onset abiraterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-onset abiraterone acetate plus prednisone (AA+P) therapy
Study: 32268436
Drug: Missed early-onset
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missed early-onset therapy assignment (MEC)
Study: 32321565
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of chemotherapy (CT)
Study: 32321565
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of chemotherapy followed by two cycles of durvalumab and subsequent maintenance treatment with durvalumab every 4 weeks
Study: 32299371
Drug: Daily weight
Normalized name: Thrifty White One Daily Weight Control Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily weight monitoring
Study: 34458922
Drug: Piperacillin/tazobactam therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam therapy
Study: 34458922
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy on the day of reoperation
Study: 34458922
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy on reoperation
Study: 35730885
Drug: Carnoy's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnoy's solution (CS)
Study: 33547717
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life (measured by Functional Assessment of Cancer Therapy-Palliative Care, range: 0-184)
Study: 36348417
Drug: Conventional neurosurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neurosurgical treatment (control)
Study: 33496811
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhaled fluticasone propionate)
Study: 32660260
Drug: EP test-guided
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP test-guided group (n=57) with adjunctive posterior wall isolation (PWI) performed in those with positive results (PWI subgroup; n=24)
Study: 35303880
Drug: BMS-986020 (LPA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986020 (LPA1 antagonist)
Study: 33125587
Drug: Treatment Ambassador
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Ambassador Program (TAP), an 8-session, peer-based, behavioral intervention
Study: 33125587
Drug: Treatment Ambassador
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Ambassador Program (TAP)
Study: 33962365
Drug: BF-FO (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF-FO (morning FO intake: DHA 1010 mg; EPA 240 mg; evening placebo: DHA 40 mg; EPA 15 mg)
Study: 33962365
Drug: DN-FO (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: DN-FO (evening FO intake: DHA 1010 mg; EPA 240 mg; morning placebo: DHA 40 mg; EPA 15 mg)
Study: 36300550
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg tablet) from Glenmark
Study: 36300550
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg tablet) from Citron
Study: 36300550
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg tablet) from Harris
Study: 36300550
Drug: Fasted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted treatment
Study: 36300550
Drug: Fed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed treatment
Study: 35302681
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens of fremanezumab
Study: 36115677
Drug: Diluted vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted vasopressin injection (20 units mixed with 100 mL normal saline)
Study: 36115677
Drug: Diluted vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted vasopressin injection (20 units mixed with 200 mL normal saline)
Study: 36115677
Drug: Diluted vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted vasopressin injection (20 units mixed with 400 mL normal saline)
Study: 616401456
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 1200 mg of glutathione once a day for eight weeks
Study: 616401456
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 0.4 g of inosine injection with 250 ml of 5% glucose once a day for eight weeks (Control)
Study: 32222912
Drug: BC 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC 007 (15 mg, 50 mg, 150 mg)
Study: 32222912
Drug: BC 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC 007 (150 mg)
Study: 32222912
Drug: BC 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC 007 (50 mg, 150 mg)
Study: 32222912
Drug: BC 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC 007 (300 mg, 450 mg, 750 mg, 1350 mg, 1900 mg)
Study: 34473029
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with complete revascularization
Study: 34473029
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical treatment with incomplete revascularization
Study: 35734514
Drug: Thiamine mononitrate
Normalized name: Thiamine Mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine mononitrate 500 mg for 90 days
Study: 34262398
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (TTG) for 4 weeks
Study: 34262398
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (TTG) for 6 weeks
Study: 32769596
Drug: Electromagnetic-focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electromagnetic-focused extracorporeal shockwave treatment (F-ESWT) with energy flux density of 0.20 mJ/mm
Study: 39250515
Drug: Resmetirom 80
Normalized name: resmetirom 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resmetirom 80 mg
Study: 35745278
Drug: Two whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two whole eggs with 70 g of spinach/day (EGG)
Study: 35978353
Drug: WeChat-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: WeChat-based cognitive behavioral therapy intervention
Study: 33209182
Drug: Proposed solutions
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed solutions for CBHI
Study: 32968936
Drug: Routine symptomatic
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine symptomatic treatment (Control)
Study: 34617959
Drug: Standard-dose heparins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose heparins
Study: 34617959
Drug: Therapeutic-dose LMWH
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose LMWH (enoxaparin, 1 mg/kg subcutaneous, twice daily)
Study: 34617959
Drug: Therapeutic-dose heparins
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose heparins
Study: 34617959
Drug: Standard-dose heparins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose heparins (non-ICU)
Study: 34617959
Drug: Therapeutic-dose heparins
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose heparins (non-ICU)
Study: 34617959
Drug: Standard-dose heparins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose heparins (ICU)
Study: 34617959
Drug: Therapeutic-dose heparins
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose heparins (ICU)
Study: 32492084
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy in addition to standard treatment (n=52)
Study: 32492084
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (control) (n=51)
Study: 33316165
Drug: Activity trackers
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity trackers with 5 daily alarms
Study: 35585556
Drug: Single-cycle intrathecal
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-cycle intrathecal therapy with two repeated injections of BM-MSCs (Lenzumestrocel) with a 26-day interval
Study: 35585556
Drug: Single-cycle intrathecal
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-cycle intrathecal therapy with two repeated injections of BM-MSCs (Lenzumestrocel) with a 26-day interval + three additional booster injections at 4, 7, and 10 months
Study: 33689236
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of furosemide
Study: 33689236
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection (BI) of furosemide
Study: 34053861
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg) plus carboplatin (AUC 5) plus pemetrexed (500 mg/m2)
Study: 36007982
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec U100 (iDeg-100)
Study: 34461080
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sildenafil citrate tablets
Study: 33048344
Drug: Dose-dense weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-dense weekly paclitaxel with 3-weekly carboplatin
Study: 32275352
Drug: Garcinia kola
Normalized name: GOTU KOLA
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia kola (bitter kola) 100 mg/kg body weight in a 200 ml solution
Study: 33138927
Drug: Outpatient motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient motivational enhancement therapy (MET, four sessions)
Study: 34375501
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both exercises
Study: 33432670
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for high-risk youth (FFT-HR)
Study: 36455146
Drug: Anti-atherosclerotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-atherosclerotic treatments (Control)
Study: 34408252
Drug: Urea +
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea + 5 Mg biochar ha-1 (B5)
Study: 34408252
Drug: Urea +
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea + 10 Mg biochar ha-1 (B10)
Study: 34408252
Drug: 5 Mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Mg biochar ha-1 (B5)
Study: 34408252
Drug: 10 Mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Mg biochar ha-1 (B10)
Study: 32065870
Drug: Trigone-including BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Trigone-including BTX-A injection template
Study: 32065870
Drug: Trigone-sparing BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Trigone-sparing BTX-A injection template
Study: 32065870
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Trigone-including and Trigone-sparing)
Study: 32955720
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU weekly) plus magnesium (250 mg daily)
Study: 33218310
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both CARE-FAM and WEP-CARE interventions
Study: 34340975
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (DEX-) implant
Study: 34340975
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (DEX- implant and bevacizumab)
Study: 32613563
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only initial periodontal treatment
Study: 32771983
Drug: Gastrointestinal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal care bundle including individualized dietary counselling weekly and rapid-access investigation and treatment for bowel symptoms.
Study: 33593767
Drug: Yellow fever,
Normalized name: Yellow fever, unspecified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever, oral typhoid, and HPV vaccines
Study: 33593767
Drug: HPV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV and tetanus/diphtheria booster vaccine
Study: 33218522
Drug: Bowen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowen Therapy (real therapy)
Study: 32986891
Drug: Baclofen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (60 mg/d)
Study: 33906073
Drug: Policaptil Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policaptil Gel Retard (PGR), 6 tablets/day
Study: 33906073
Drug: Metformin, 1500–2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 1500–2000 mg/day in two divided doses
Study: 32840955
Drug: Professionally-based cognitive-behavioral
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally-based cognitive-behavioral therapy for insomnia (PCBT-I)